Organs

BERLIN HEALS Announces results of first-in-human study for its Implantable C-MIC device for the Treatment of Heart Failure with Electrical Microcurrent and the Launch of a pivotal CE Mark Study

Retrieved on: 
Thursday, March 4, 2021
Branches of biology, Anatomy, Medical technology, Biomedical engineering, Prosthetics, Cardiac electrophysiology, Heart, Organs, Implant

The C-MIC is a small implantable device that delivers a minimal constant electrical DC current to the heart.

Key Points: 
  • The C-MIC is a small implantable device that delivers a minimal constant electrical DC current to the heart.
  • The results show significant, rapid improvements in heart function, heart size and quality of life of patients.
  • Thus, this treatment has the potential to become the first sustainable, almost curative, treatment for heart failure in patients with unmet medical needs.
  • Since 2014, the Berlin Heals team has been developing a new and revolutionary technology to treat heart failure.

Mallinckrodt Provides Regulatory Update on StrataGraft®

Retrieved on: 
Friday, February 12, 2021
Health sciences, Anatomy, Organs, Branches of biology, Clinical research, Routes of administration, Clinical trial, Design of experiments, Pharmaceutical industry, Human skin, Dermis, Mallinckrodt

An engineered, bilayer construct, StrataGraft is designed to mimic natural human skin with both inner dermis-like and outer epidermis-like layers.

Key Points: 
  • An engineered, bilayer construct, StrataGraft is designed to mimic natural human skin with both inner dermis-like and outer epidermis-like layers.
  • Mallinckrodt is currently conducting a StrataGraft continued access clinical trial (StrataCAT, NCT04123548) under an Expanded Access Program (EAP).
  • Additionally, Mallinckrodt plans to conduct a study evaluating StrataGraft in the treatment of pediatric populations.
  • This release includes forward-looking statements concerning StrataGraft, including the regulatory review process, its potential impact on patients and anticipated benefits associated with its use, and future clinical trial plans.

BioVentrix Receives 2021 NUB Status 1 Reimbursement Renewal in Germany for the Revivent TC TransCatheter Ventricular Enhancement System

Retrieved on: 
Monday, February 8, 2021
Surgery, Medical devices, Health, Clinical trials, Cardiology, Circulatory system, Medical devices, Interventional cardiology, Cardiology, Medicine, RTT, Heart, Organs, Revivent

LIVE Therapy uses the Revivent TC System to exclude scar tissue on the left ventricle that has occurred from a heart attack so the healthy portion of the heart can operate more efficiently.

Key Points: 
  • LIVE Therapy uses the Revivent TC System to exclude scar tissue on the left ventricle that has occurred from a heart attack so the healthy portion of the heart can operate more efficiently.
  • The Revivent TC System has received the CE Mark and is commercially available in Europe, where adoption is expanding.
  • In the U.S., the company is currently enrolling patients in its pivotal trial of the Revivent TC System, the ALIVE Trial.
  • Less invasive ventricular reconstruction for ischemic heart failure.

Global Gastric Cancer Forecast and Market Analysis to 2027: No Targeted Therapies Exist for Locoregional Disease, Although Opdivo and Keytruda are in Ongoing Phase III Trials for this Setting - ResearchAndMarkets.com

Retrieved on: 
Friday, January 29, 2021
General Health, Pharmaceutical, Health, Oncology, Branches of biology, Abdomen, Digestive system, Clinical medicine, Membrane biology, Cancer treatments, Organs, Stomach cancer, Muscularis mucosae, Stomach, Muscularis, Submucosa

Stomach or gastric cancer (GC) refers to any cancer arising in the lining of the stomach.

Key Points: 
  • Stomach or gastric cancer (GC) refers to any cancer arising in the lining of the stomach.
  • In most cases, gastric adenocarcinomas will begin in the muscularis mucosae and submucosa, then invading deeper lamina of the gastric wall.
  • The majority of gastric cancer diagnoses (66.1%) worldwide are in males, ranging from 54.3% to 68.3% across regions.
  • No targeted therapies exist for locoregional disease, although Opdivo and Keytruda are in ongoing Phase III trials for this setting.

US Bladder Cancer Market and Competitive Landscape Report 2021: Epidemiology, Key Products, Market Valuations and Forecast, Drugs Sales and Market Shares - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 26, 2021
Health, General Health, Aging-associated diseases, Infectious causes of cancer, Branches of biology, Organs, Pelvis, Urinary bladder, Urinary system, Bladder cancer, Cancer, Epidemiology of cancer, Health, Clinical medicine

US Bladder Cancer Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Bladder Cancer pipeline products, Bladder Cancer epidemiology, Bladder Cancer market valuations and forecast, Bladder Cancer drugs sales and competitive landscape in the US.

Key Points: 
  • US Bladder Cancer Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Bladder Cancer pipeline products, Bladder Cancer epidemiology, Bladder Cancer market valuations and forecast, Bladder Cancer drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Bladder Cancer treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Bladder Cancer pipeline: Find out the products in clinical trials for the treatment of Bladder Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Bladder Cancer drugs: Identify key products marketed and prescribed for Bladder Cancer in the US, including trade name, molecule name, and company
    Bladder Cancer market valuations: Find out the market size for Bladder Cancer drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Bladder Cancer drugs market share: Find out the market shares for key Bladder Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Bladder Cancer products

Danish PUCA Pure and Care Collagen Product Available in America

Retrieved on: 
Friday, January 22, 2021
Branches of biology, Organs, Structural proteins, Ageing, Anatomy, Skin, Wrinkle, Collagen, Human skin

PALM BEACH, FL, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Collagen Serum by PUCA Pure & Caredecreases the appearance of fine lines and wrinkles.

Key Points: 
  • PALM BEACH, FL, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Collagen Serum by PUCA Pure & Caredecreases the appearance of fine lines and wrinkles.
  • Our Collagen Serum is one of our most popular skincare products, said Vivian Dynesen, founder and CEO of the Danish beauty company, PUCA Pure & Care.
  • Collagen Serum, along with five other Puca Pure & Care products, is now available at vitabeauti.com :
    Collagen Serum, which stimulates the skins collagen, promotes skin elasticity, decreases the appearance of fine lines and wrinkles, and promotes balanced moisture in the skin.
  • Every PUCA Pure & Care product is tested to ensure its effectiveness on all skin types, including hypersensitive skin.

DGAP-News: BRAIN AG publishes its Annual Report for the Financial Year 2019/20

Retrieved on: 
Thursday, January 14, 2021
Chemistry, Physical sciences, Natural sciences, Animal anatomy, Brain, Organs, Forward-looking statement, Silver

Biotechnology Research and Information Network AG ("BRAIN AG") published its annual report 2019/20 including the detailed consolidated financial statements for the financial year 2019/20.

Key Points: 
  • Biotechnology Research and Information Network AG ("BRAIN AG") published its annual report 2019/20 including the detailed consolidated financial statements for the financial year 2019/20.
  • With liquid funds of EUR 18.9 million, BRAIN AG maintains a strong capital base for the expected future growth of the company.
  • Numerous factors exist that could influence the future performance by, and future developments at, BRAIN AG and the BRAIN Group.
  • BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Zhongchao Inc. Promotes Standardized Liver Cancer Diagnosis and Treatment with Medical Associations and Experts

Retrieved on: 
Wednesday, January 13, 2021
Health, Hepatology, Medicine, Medical terminology, Liver, Organs, Medical guideline, Cancer

In 2020, Zhongchao worked with medical associationsand experts to jointly carry out a multi-year online education project on the diagnosis and treatment of primary liver cancer.

Key Points: 
  • In 2020, Zhongchao worked with medical associationsand experts to jointly carry out a multi-year online education project on the diagnosis and treatment of primary liver cancer.
  • This project aims to promote and implement the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 Edition) (the "Guidelines") published by the National Health Commission of the People's Republic of China.
  • The Annual Conference provided a timely platform for us to review last year's trainings on the standardized liver cancer diagnosis and treatment.
  • The Guidelines will undergo a new round of update in 2021 to meet the demand of rapid developments in liver cancer diagnosis and treatment in recent years.

Axcella Announces IND Clearance for AXA1665, Program Updates and 2021 Milestones

Retrieved on: 
Monday, January 11, 2021
Research, FDA, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Liver, Organs, Encephalopathy

In the second quarter of 2021, Axcella plans to initiate a Phase 2 trial of AXA1665.

Key Points: 
  • In the second quarter of 2021, Axcella plans to initiate a Phase 2 trial of AXA1665.
  • The trial will be conducted globally with the primary endpoint assessing change in the psychometric hepatic encephalopathy score (PHES) after 24 weeks of treatment.
  • Based on the totality of the findings to date, Axcella has decided not to expand enrollment in the AXA4010-001 study.
  • Axcella plans to provide an update on its research and development activities and share details about opportunities it has identified for pipeline expansion later in 2021.

ProMind Complex Review: New Brain Boosting Supplement to Improve Memory

Retrieved on: 
Monday, January 11, 2021
Animal anatomy, Brain, Organs, Nootropic

The working of the ProMind Complex on the brain is quite complicated, primarily because of the brain's complexity.

Key Points: 
  • The working of the ProMind Complex on the brain is quite complicated, primarily because of the brain's complexity.
  • ProMind Complex optimizes the brain functions by activating all required brain pathways.
  • Unlike other nootropics that tend to have side effects on the brain, ProMind Complex is risk-free and safe for daily consumption.
  • In only a few years after its launch, ProMind Complex has already become a big name in the supplement industry .